Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

MLA

Smyth L, et al. Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer. Jan. 2020. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.RECOLECTA.....629eea8c6359202c299d269fd292af7f&authtype=sso&custid=ns315887.

APA

Smyth L, Piha-Paul S, Won H, Schram A, Saura C, Loi S, Lu J, Shapiro G, Juric D, Mayer I, Arteaga C, de la Fuente M, Brufksy A, Spanggaard I, Mau-Sorensen M, Arnedos M, Moreno V, Boni V, Sohn J, … Hyman D. (2020). Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.

Chicago

Smyth L, Piha-Paul S, Won H, Schram A, Saura C, Loi S, Lu J, et al. 2020. “Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer,” January. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.RECOLECTA.....629eea8c6359202c299d269fd292af7f&authtype=sso&custid=ns315887.